Journal of Reproduction & Infertility

Journal of Reproduction & Infertility

NUCB2/Nesfatin-1 in the Blood and Follicular Fluid in Patients with Polycystic Ovary Syndrome and Poor Ovarian Response

Authors
1 Department of Clinical Biochemistry, University of Health Sciences, Elazig Fethi Sekin City Hospital, Elazig, Turkey
2 Department of Obstetrics and Gynecology, School of Medicine, Firat University, Elazig, Turkey
3 Department of Clinical Biochemistry, Kovancilar State Hospital, Taipei City, Turkey
4 Department of Internal Medicine (Endocrinology and Metabolism Diseases), School of Medicine, Firat University, Elazig, Turkey
5 Department of Medical Biochemistry and Clinical Biochemistry (Firat Hormones Research Group), Medical School, Firat University, Elazig, Turkey
6 Department of Medical Biology, Medical School, Erzincan Binali Yildirim University, Elazig, Turkey
7 School of Medicine, Medical School Student, Firat University, Elazig, Turkey
Abstract
Background: Failure to respond adequately to standard protocols and to recruit adequate follicles is called ‘poor ovarian response’. The relationships between metabolic alterations and NUCB2/Nesfatin-1 levels were explored in patients with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization/intracytoplasmic sperm injection. Methods: This case-control study involved 20 infertile women with PCOS and 20 control women diagnosed as poor ovarian responders stimulated with a GnRH antagonist. Blood samples were taken during ovum pick-up and follicular fluids (FF) were obtained from a dominant follicle from the subjects. Samples were analyzed by using ELISA. Statistical analysis was performed with SPSS version 20. Data are expressed as means ± standard deviation (SD). Results: Blood NUCB2/Nesfatin-1 levels in PCOS were significantly lower (p=0.011) while the NUCB2/Nesfatin-1 levels of FF in poor ovarian response (POR) were higher, but not statistically significant. Insulin, total testosterone, fasting glucose, homeostasis model assessment, and insulin resistance index in women with POR decreased when compared with PCOS. Blood NUCB2/Nesfatin-1 levels were significantly higher than FF NUCB2/Nesfatin-1 levels in both groups (p<0.001). Moreover, a positive correlation was detected between blood NUCB2/Nesfatin-1 and testosterone (p=0.602, r=0.304), HOMA-IR (p=0.252, r=0.384), BMI (p=0.880, r=0.44) in PCOS, but it was not significant. Conclusion: NUCB2/Nesfatin-1 levels might be important in follicular growth in PCOS subjects undergoing IVF/ICSI with an antagonist protocol and NUCB2/Nesfatin-1 level could reliably help to predict poor ovarian response.
Keywords

  1. Deniz R, Gurates B, Aydin S, Celik H, Sahin İ, Baykus Y, et al. Nesfatin-1 and other hormone alterations in polycystic ovary syndrome. Endocrine. 2012;42(3):694-9.
  2. Gault JM, Davis R, Cascella NG, Saks ER, Corripio-Collado I, Anderson WS, et al. Approaches to neuromodulation for schizophrenia. J Neurol Neurosurg Psychiatry. 2018;89(7):777-87.
  3. Alp E, Görmüş U, Güdücü N, Bozkurt S. Nesfatin-1 levels and metabolic markers in polycystic ovary syndrome. Gynecol Endocrinol. 2015;31(7):543-7.
  4. Azziz R. PCOS in 2015: New insights into the genetics of polycystic ovary syndrome. Nat Rev Endocrinol. 2016;12(2):74-5.
  5. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv. 2004;59(2):141-54.
  6. Ayada C, Toru Ü, Korkut Y. Nesfatin-1 and its effects on different systems. Hippokratia. 2015;19(1):4-10.
  7. García-Galiano D, Navarro VM, Roa J, Ruiz-Pino F, Sánchez-Garrido MA, Pineda R, et al. The anorexigenic neuropeptide, nesfatin-1, is indispensable for normal puberty onset in the female rat. J Neurosci. 2010;30(23):7783-92.
  8. Chung Y, Kim H, Im E, Kim P, Yang H. Th 17 cells and nesfatin-1 are associated with spontaneous abortion in the CBA/j× DBA/2 mouse model. Dev Reprod. 2015;19(4):243-52.
  9. Feng R, Sang Q, Zhu Y, Fu W, Liu M, Xu Y, et al. MiRNA-320 in the human follicular fluid is associated with embryo quality in vivo and affects mouse embryonic development in vitro. Sci Rep. 2015;5:8689.
  10. Ademoglu EN, Gorar S, Carlıoglu A, Dellal FD, Berberoglu Z, Akdeniz D, et al. Plasma nesfatin-1 levels are increased in patients with polycystic ovary syndrome. J Endocrinol Invest. 2014;37(8):715-9.
  11. Zamah AM, Hsieh M, Chen J, Vigne JL, Rosen MP, Cedars MI, et al. Human oocyte maturation is dependent on LH-stimulated accumulation of the epidermal growth factor-like growth factor, amphiregulin. Hum Reprod. 2010;25(10):2569-78.
  12. Aydin S. A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA. Peptides. 2015;72:4-15.
  13. Dore R, Levata L, Lehnert H, Schulz C. Nesfatin-1: functions and physiology of a novel regulatory peptide. J Endocrinol. 2017;232(1):R45-65.
  14. Seon S, Jeon D, Kim H, Chung Y, Choi N, Yang H. Testosterone regulates NUCB2 mRNA expression in male mouse hypothalamus and pituitary gland. Dev Reprod. 2017;21(1):71-8.
  15. Aslan M, Celik O, Celik N, Turkcuoglu I, Yilmaz E, Karaer A, et al. Cord blood nesfatin-1 and apelin-36 levels in gestational diabetes mellitus. Endocrine. 2012;41(3):424-9.
  16. Li QC, Wang HY, Chen X, Guan HZ, Jiang ZY. Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul Pept. 2010;159(1-3):72-7.
  17. Haider D, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia. 2006;49(8):1909-14.
  18. Su Y, Zhang J, Tang Y, Bi F, Liu JN. The novel function of nesfatin-1: anti-hyperglycemia. Biochem Biophys Res Commun. 2010;391(1):1039-42.
  19. Gao X, Zhang K, Song M, Li X, Luo L, Tian Y, et al. Role of nesfatin-1 in the reproductive axis of male rat. Sci Rep. 2016;6:32877.
  20. Xu Y, Zhang H, Li Q, Lao K, Wang Y. The role of nesfatin-1 expression in letrozole-induced polycystic ovaries in the rat. Gynecol Endocrinol. 2017;33(6):438-41.
  21. Celik O, Yesilada E, Hascalik S, Celik N, Sahin I, Keskin L, et al. Angiotensin-converting enzyme gene polymorphism and risk of insulin resistance in PCOS. Reprod Biomed Online. 2010;20(4):492-8.
  22. Llaneza-Suarez D, Llaneza P, González C, De-La-Fuente P, García-Ochoa C, Garrido P, et al. Assessment of follicular fluid leptin levels and insulin resistance as outcome predictors in women undergoing in vitro fertilization–intracytoplasmic sperm injection. Fertil Steril. 2014;102(6):1619-25.
  23. Blüher M, Mantzoros CS. From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. Metabolism. 2015;64(1):131-45.
  24. Mantzoros CS, Cramer DW, Liberman RF, Barbieri RL. Predictive value of blood and follicular fluid leptin concentrations during assisted reproductive cycles in normal women and in women with the polycystic ovarian syndrome. Hum Reprod. 2000;15(3):539-44.
  25. Catak Z, Aydin S, Sahin İ, Kuloglu T, Aksoy A, Dagli AF. Regulatory neuropeptides (ghrelin, obestatin and nesfatin-1) levels in blood and reproductive tissues of female and male rats with fructose-induced metabolic syndrome. Neuropeptides. 2014;48(3):167-77.
  26. Fedorcsák P, Dale PO, Storeng R, Tanbo T, Abyholm T. The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome. Hum Reprod. 2001;16(6):1086-91.
  27. Broughton DE, Moley KH. Obesity and female infertility: potential mediators of obesity's impact. Fertil Steril. 2017;107(4):840-7.
  28. Crosignani PG, Ragni G, Parazzini F, Wyssling H, Lombroso G, Perotti L. Anthropometric indicators and response to gonadotrophin for ovulation induction. Hum Reprod. 1994;9(3):420-3.
  29. Wass P, Waldenström U, Rössner S, Hellberg D. An android body fat distribution in females impairs the pregnancy rate of in-vitro fertilization-embryo transfer. Hum Reprod. 1997;12(9):2057-60.
  30. Wang JX, Davies MJ, Norman RJ. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum Reprod. 2001;16(12):2606-9.